buthionine sulfoximine has been researched along with sorafenib in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chang, Y; Cho, EJ; Cho, H; Cho, YY; Jo, A; Kim, JB; Kim, YJ; Lee, JH; Lee, M; Lee, S; Nam, JY; Yoon, JH; Yu, SJ | 1 |
1 other study(ies) available for buthionine sulfoximine and sorafenib
| Article | Year |
|---|---|
3-bromopyruvate and buthionine sulfoximine effectively kill anoikis-resistant hepatocellular carcinoma cells.
Topics: Anoikis; Antineoplastic Agents; Buthionine Sulfoximine; Carcinoma, Hepatocellular; Epithelial-Mesenchymal Transition; Hep G2 Cells; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Pyruvates; Reactive Oxygen Species; Sorafenib | 2017 |